Literature DB >> 9789534

SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available.

M S Horowitz1, J C Pehta.   

Abstract

Clinical studies of SD-Plasma (SDP) have included treatment of patients with both the acute and chronic relapsing (CRTTP) forms of TTP and replacement of coagulation factors in patients with congenital deficiencies. With the infusion of SDP in 6 patients with CRTTP, platelet counts rose, LDH values dropped, hemoglobin levels remained constant, and the patients continued in good health. In an FFP-controlled study in acute TTP, 16 patients were exchanged with SDP and 10 with FFP. There was no difference between the two groups in patient survival; relapse or remission rate; incidence of treatment resistance; or in per patient total volume infused, number of treatments, average volume per treatment, or number of relapses. Finally, 48 coagulation factor-deficient patients received SDP for surgical prophylaxis, active bleeding and routine prophylaxis for Factor XIII deficiency. The expected levels of the deficient factors were achieved, and the treating physicians concluded that there was control of bleeding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9789534     DOI: 10.1111/j.1423-0410.1998.tb05478.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  5 in total

1.  Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Authors:  Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

2.  Coagulation factors V, VIII, and X, prothrombin time and activated partial thromboplastin time test results in thawed plasma stored at 1-6 ºC for 5 days.

Authors:  Hossin Timori Naghadeh; Mahtab Maghsudloo; Mohammad Reza Tabatabaei
Journal:  Blood Transfus       Date:  2011-01       Impact factor: 3.443

3.  Virus-inactivated plasma - Plasmasafe: a one-year experience.

Authors:  Giustina De Silvestro; Paola Bagatella; Tiziana Tison; Vania Quaino; Paolo Carraro; Maria Luisa Tenderini; Annarosa Lazzaro; Alberto Marotti
Journal:  Blood Transfus       Date:  2007-07       Impact factor: 3.443

Review 4.  Pathogen inactivation techniques.

Authors:  J P R Pelletier; S Transue; E L Snyder
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

5.  Solvent/detergent plasma: pharmaceutical characteristics and clinical experience.

Authors:  Giancarlo Maria Liumbruno; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.